Hear 55+ Presentations from Top Pharma at Drug Discovery Chemistry in San Diego

Cambridge Healthtech Institute's 14th Annual Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma and biotech. As in the past, speaker participation by industry is once again very strong, with presentations from, and discussions/trainings led by, AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, F. Hoffmann-La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, and Takeda. Preview the more than 55 presentations* below:

Considerations in the Generation of Covalent BTK Inhibitors
Noel S. Wilson, MSc, Senior Scientist III, Discovery Chemistry and Technology

Ligand-Receptor Molecular Interactions and Drug Design
Maricel Torrent, PhD, Principal Scientist, Molecular Modeling

AMG176, a Selective MCL-1 Targeted Drug Candidate
Paul E. Hughes, PhD, Principal Scientist, Oncology Research

Modeling and Simulation to Study the Impact of Transporters on Drug Disposition and to Improve in vitro to in vivo Extrapolation (IVIVE)
Priyanka Kulkarni, PhD, Scientist, Pharmacokinetics and Drug Metabolism

Success and Challenges in Predicting Transporter Mediated Drug Disposition and Clearance from in vitro to in vivo Extrapolation
Na Li, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism

Discovery of AZD5991, a Potent and Selective Macrocyclic Mcl-1 Inhibitor for Treatment of Cancer
Scott Mlynarski, PhD, Senior Scientist, Oncology Chemistry, IMED Biotech Unit

The Discovery of Novel Allosteric MEK1 Binders by Fragment-Based Approaches
Paolo Di Fruscia, PhD, Senior Scientist, Structure Biophysics & FBLD, Discovery Sciences, IMED Biotech Unit

DEL for Membrane Proteins: Case Study of a GPCR
Dean G. Brown, PhD, Director, External Chemistry, Hit Discovery, Discovery Sciences, IMED Biotech Unit

Artificial Intelligence in Kinase Inhibitor Discovery
Istvan J. Enyedy, PhD, Principal Scientist

Structural and Functional Characterization of Phospholipases as a Target for ALS
Jay Chodaparambil, PhD, Research Scientist, Chemical and Molecular Therapeutics

Design of an Artificial Intelligence System for Drug Discovery
Istvan Enyedy, PhD, Principal Scientist

Boehringer Ingelheim
Empirical & Structure-Based PROTAC Design: Lessons Learned with VHL-Based PROTACs
Peter Ettmayer, PhD, Scientific Director, Cancer Research

Bristol-Myers Squibb
The Good, the Bad, and the Confusing: Binding Kinetics at GPCR Targets and Potential Effects on Lead Optimization and Translatability
Brian Murphy, PhD, Senior Principal Scientist, CV and Fibrosis Drug Discovery, Disease Sciences and Biologics, R&D

Cereblon Neosubstrate Degradation in Efficacy and Teratogenecity
Philip Chamberlain, DPhil, Senior Director, Structural and Chemical Biology

Solving a 60-Year Mystery: SALL4 Mediates Teratogenicity as a Thalidomide-Dependent Substrate of Cereblon
Mary Matyskiela, PhD, Principal Scientist, Structural and Chemical Biology

ADME Strategies in Beyond the Rule of Five Space
Ganesh Rajaraman, PhD, MBA, Associate Director, DMPK

Eli Lilly
Targeting the Tumor Microenvironment with TGFβ Inhibitors
Rikke B. Holmgaard, PhD, Principal Research Scientist, Oncology Research

BACE Inhibitor Drug Discovery - From Fragment-Based Hits to Clinical Candidates
Erik J. Hembre, PhD, Research Fellow, Discovery Chemistry Research

Discovery of Novel and Potent Spirocyclic RORγt Inhibitors
Chip Lugar, Senior Research Scientist, Discovery Chemistry Research

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor
Dustin Mergott, Senior Research Advisor, Group Leader, Discovery Chemistry Research & Technologies

Immunology Basics for Chemists
Songqing Na, PhD, Senior Scientist, Biotechnology & Autoimmunity Res-AME

Targeting Innate Immunity
Daniel Dairaghi, PhD, Senior Research Advisor, Medicinal Chemistry

Phage Display
Sepideh Afshar, PhD, Principal Research Scientist, Department of Protein Engineering

EMD Serono
A Kinase Platform for the Discovery of Reversible and Covalent Kinase Inhibitors
Igor Mochalkin, PhD, Associate Director

F. Hoffmann-La Roche
Targeting RNA: Discovery of Risdiplam; a Selective SMN2 Gene Splicing Modulator for the Treatment of Spinal Muscular Atrophy
Hasane Ratni, PhD, Expert Scientist, Medicinal Chemistry

Genentech, Inc.
Targeting the CBP/P300 Bromodomain for Immuno-Oncology
Karen Gascoigne, PhD, Scientist, Discovery Oncology

Antibody-Mediated Delivery of Protein Degraders
Peter Dragovich, PhD, Staff Scientist, Discovery Chemistry

Targeting Ubiquitin Ligases in Inflammatory Diseases
Domagoj Vucic, PhD, Principal Scientist, Early Discovery Biochemistry

Discovery of a Cross-Species Potent and Selective Inhibitor of Receptor-Interacting Protein Kinase (RIPK1) Providing Protection in a Number of Immunological Models
Snahel Patel, PhD, Scientist, Discovery Chemistry

Biotransformation of Antibody Drug Conjugates (ADCs) - Pathways and Enzymes
Donglu Zhang, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics

Determining the Clinical Relevance of DDI Predictions
Kari Morrissey, PhD, Scientist, Clinical Pharmacology

Advanced Biophysical Methods for Driving Lead Generation in the Right Direction
Mela Mulvihill, PhD, Scientist, Biochemical & Cellular Pharmacology

Methodologies for Optimizing Drug Clearance and Drug-Drug Interactions
Zhengyin Yan, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics
Donglu Zhang, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics

Emerging Targets for Cancer Immunotherapy
Aditya Murthy, PhD, Scientist, Cancer Immunology

Gilead Sciences, Inc.
Discovery of GS-9876: A Selective SYK Inhibitor for the Treatment of Autoimmune Inflammatory Disorder
Peter Blomgren, PhD, Research Scientist II, Medicinal Chemistry

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle
Petr Jansa, PhD, Senior Research Scientist II, Medicinal Chemistry

Proteolysis Targeting Chimeric Molecules (PROTACs) as Small Molecule Modality in Immuno-Oncology
Markus Queisser, PhD, Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery

Discovery and Optimization of Potent and Selective TYK2 Pseudokinase Inhibitors through DNA-Encoded Library Technology
Ghotas Evindar, PhD, Head, Drug Design and Selection, Medicinal Science & Technology

Case Study: Optimization of a DEL Drug Candidate, RIP1K
Heather O'Keefe, PhD, Investigator, Medicinal Science and Technology

Small Molecule-Induced Protein Degradation with Proteolysis Targeting Chimeric Molecules (PROTACs)
Markus Queisser, PhD, Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery

Diversity-Oriented Platforms for Ligand Discovery: Focusing on DNA-Encoded Libraries
Svetlana Belyanskaya, PhD, Encoded Library Technologies, R&D Platform Technology & Science
Ghotas Evindar, PhD, Head, Post-Selection Chemistry Group, Encoded Library Technologies, R&D Platform Technology & Science

Gene Signature Screen (GSS) to Identify Novel Modulators of a Transcriptional Factor
Seong Joo Koo, PhD, Senior Scientist, Lead Discovery

A New Era in Discovery of Solute Carrier (SLC) Transporter Modulators
Alan D. Wickenden, PhD, Scientific Director, Discovery Science

Methods to Identify PPI Modulators
Samantha J. Allen, PhD, Principal Scientist, Screening

Application of Fragment-Based Drug Discovery in the Identification of Novel FXIa Inhibitors for Thrombosis Prevention
Santhosh F. Neelamkavil, PhD, Director, Discovery Chemistry

An Alternate Inhibition Mechanism for the Deubiquitinase USP7 and its Consequences for Ubiquitin Chain Linkage Selectivity
Till Maurer, PhD, Director, NMR-Lead, Analytical Enabling Technologies

Third Wave of Macrocyclic Peptide Therapeutics: Benchmarking and Druggable Target Space
Tomi K. Sawyer, PhD, Distinguished Scientist, Peptide Drug Discovery & Innovative Technologies

Characterization of Novel STING Ligands Using SPR and Orthogonal Approaches
Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology

Integrating Fragment, HTS and DEL Hit-finding Approaches
Robert D. Mazzola, PhD, Director, Chemical Research

Fragment-Based Drug Discovery Campaigns with Protein Complexes that Mediate Protein-Protein Interactions
Charles Wartchow, PhD, Senior Investigator

Discovery of ABL001, an Allosteric Inhibitor of Bcr-Abl Kinase
Wolfgang Jahnke, PhD, Director and Leading Scientist, Chemical Biology and Therapeutics

Targeted Degradation of Bruton's Tyrosine Kinase (BTK)
Matthew Calabrese, PhD, Senior Principal Scientist and Structural Biology Lab Head, Structural and Molecular Sciences

Binding Kinetics and Thermodynamics to Understand and Enhance Selectivity of Kinase Inhibitors
Prakash Palde, PhD, Principal Scientist, Oncology Research Unit

Employing Photoredox Catalysis for the Synthesis of DNA- Encoded Libraries
Dominik Koelmel, PhD, Senior Scientist, DNA-Encoded Libraries

Characterization of Specific Naa50 Inhibitors Identified using a DNA Encoded Library: a Lead-Finding Case Study for a Challenging Target
Pei-Pei Kung, PhD, Associate Research Fellow, Medicinal Chemistry

Discovery to Approval: Medicinal Chemistry Retrospective of Lorlatinib, A Macrocyclic ALK Inhibitor for Metastatic and Resistance Non-Small Cell Lung Cancer
Ted. W. Johnson, PhD, Research Fellow, Design Chemistry

Quantitative Prediction of Complex Drug-Drug Interactions Involving CYP3A and P-glycoprotein: A Case Study of Anticancer Drug Bosutinib
Shinji Yamazaki, PhD, Department of Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories

Engaging Kinases in Living Cells: Probing Drug-Target Interactions with Chemical Biology and Biophysical Tools
Jordan Carelli, PhD, Senior Scientist, Oncology RU

CryoEM Applied to Drug Discovery
Seungil Han, PhD, Associate Research Fellow, Structure Biology & Biophysics

A Chemical Toxicologist's Perspective on the Validation and Application of Cutting-Edge in vitro Toxicity Assays for Lead Optimization
Tomoya Yukawa, PhD, Associate Scientific Fellow, Discovery Toxicology, Drug Safety Research & Evaluation

* As of 2/13/19 – Please see individual agenda pages for most up-to-date list of speakers